PhenoAge: A Clock Trained on Blood Tests
The costly DNA version of PhenoAge is trained to imitate a nine-number blood score, which a routine lab could have handed you already.

Here is a small fact about PhenoAge: the expensive version, the one read off your DNA, is trained to predict the cheap version, the one read off an ordinary blood test. The cheap version, from a PLOS Medicine study built on NHANES data, is “calculated as a linear combination of chronological age and 9 multi-system clinical chemistry biomarkers.” Those include creatinine, blood glucose, C-reactive protein and lymphocyte percentage. You take a person’s age and nine numbers a routine lab already reports, multiply each by a weight, add them up, and out comes an age.
The expensive version, called DNAm, reads methylation at hundreds of CpG sites on the genome. Its target is not the person’s birthday. It is that nine-marker blood score. So the short answer is that the clock is a weighted blend of blood chemistry, and its molecular sibling is an estimate of that blend made from a different kind of sample. Both are meant to say something about disease and death beyond what age alone says. How precisely either one describes a single person is less settled.
What PhenoAge is built from, the dumb version
I mean “dumb” as a compliment here. The blood version requires no special equipment. The inputs are things a hospital lab produces every day for other reasons (kidney function, sugar, inflammation, white cell mix, etc.), and the output is arithmetic.
Stated with the gravity it deserves: whereas the subject has had blood drawn; and whereas the laboratory has, in the ordinary course of its business, reported a creatinine value; and whereas the parties agree that creatinine shall be multiplied by a coefficient; now therefore the subject is 47. No sequencing, no kit and no shipping label are involved, and the coefficients fit on an index card.
The dumb version is also hard to improve on by much. A cancer cohort study built GeroAge, which uses only six blood markers plus age, and reported R=0.99 agreement with PhenoAge and similar power to predict overall survival in NHANES data. Going the other direction, a 25-biomarker clock trained on UK Biobank data (n = 306,116) with an Elastic-Net Cox model, picking from 60 circulating biomarkers, reached a C-Index of 0.778 for mortality. That was a lift of 0.028 over PhenoAge, which the write-up describes as an 11% relative increase in predictive value. Drop three markers and nothing much happens. Add sixteen and you get a real but modest bump.
I feel like that is the most informative fact about the blood clock. Most of the signal lives in a handful of common lab values.
It is a bit like a quarterback passer rating. Nobody thinks the formula is the essence of quarterbacking, but it is built from numbers that already exist, and it tracks winning well enough that people keep using it.
How DNAm PhenoAge reaches the same number by a longer road
The first epigenetic clocks, such as Horvath’s, were trained to predict chronological age, which is a strange thing to predict (you can just ask). CD Genomics describes what happened next: second-generation clocks “changed the training objective from predicting chronological age to predicting clinical phenotypes, incidence of disease, and all-cause mortality associated with aging.” DNAm PhenoAge is one of those. The DunedinPACE paper cites it as Levine et al. 2018. The Scientist lists Steve Horvath as having developed and validated it, alongside the Horvath clock, GrimAge and DunedinPACE.
The sophisticated road goes like this. You draw blood, or collect some other sample. You extract DNA. You run it on a methylation array (one adolescent lead-exposure study, for instance, used Infinium MethylationEPIC BeadChips). You read methylation at hundreds of CpG sites. You feed those through a regression whose weights were chosen so the result lines up with phenotypic age, the nine-marker blood score. And you arrive at an estimate of a number the lab could have handed you from the same tube.
Here is the conversation I imagine at some point in the pipeline:
“Hey, we already have the glucose.”
“Sure, but this is the glucose’s methylation.”
That is unfair, but only a little. DNAm PhenoAge is what powers at least one consumer product: Elysium Health says its Index test uses the DNAm PhenoAge biomarker as the basis of its biological age measurement. The methylation version can be sold as a kit, because the sample can be collected outside a clinic. The blood version needs a lab order and a phlebotomist. In product terms, the methylation clock is the one that gets to flirt with customers directly, while the blood panel stays home with the doctor.
Why train a clock to predict another clock
One reading is that methylation captures something the blood panel misses. Chemistry values bounce around with last night’s dinner or a cold; a methylation pattern might reflect a slower, accumulated state. If so, the long road is worth walking, because you end up near the same place with less day-to-day weather in the measurement.
The second reading is that the methylation version is mostly a costlier, noisier reproduction of a number you could compute directly, and that its appeal is the sample, not the science. The facts here do not choose between these. The clock was built to agree with the blood score, so agreement alone cannot tell you which reading is right.
There is some evidence the second-generation design picks up life circumstances better than first-generation clocks. In the Add Health study of younger U.S. adults, sociodemographic and lifestyle factors “were more often associated with biological aging” in clocks like PhenoAge, GrimAge and DunedinPACE than in clocks trained on chronological age alone, like Horvath. That’s fine as far as it goes. It says the target matters. It does not say the methylation route beats the blood route to the same target.
How much the number moves when you measure it twice
This is where the long road gets weird. Elysium Health, which sells a test based on DNAm PhenoAge, also reports that technical replicates of published clocks (Horvath, Hannum, PhenoAge) produced deviations of three to nine years between replicate measurements. A replicate is the same sample run again. The person did not age between runs; the lab work just disagreed with itself.
Sample type adds its own problem. The Scientist notes that almost all clocks used in commercial tests are trained on blood, and that applying a blood-trained clock to saliva “without correction can produce substantial errors,” because the cells in saliva carry different methylation signatures.
Now a scenario, which is invented. Suppose someone runs the same sample twice and gets 41 and then 49. They average to 45. To tighten it they run it four more times, then sixteen, until the standard error is smaller than a birthday. At that point they have spent a great deal of effort to estimate, with some precision, a number that a creatinine test, a glucose test and seven friends would have produced in an afternoon. Then they get a cold, the blood panel shifts, and the thing they were so carefully estimating has moved anyway.
(I write about blood tests on the internet, so this is roughly the most exciting plot my job allows.)
What changes PhenoAge, according to the studies
Studies use PhenoAge constantly, usually alongside other clocks, and the clocks do not always move together. People with HIV who started antiretroviral therapy saw epigenetic age acceleration partly reverse across Horvath, Hannum, GrimAge and PhenoAge, but PhenoAge and GrimAge stayed significantly elevated versus HIV-negative controls after two years. In an organophosphate pesticide study, estimated mixture effects rose at higher exposure for Horvath, Hannum and PhenoAge but not GrimAge or GrimAge2. A cortisol-to-DHEAS ratio correlated with Hannum, Horvath Skin & Blood and PhenoAge, but not Horvath or GrimAge. Among men with Parkinson’s disease in the PPMI cohort, faster aging on Horvath v1, PhenoAge and GrimAge went with worse tremor, gait and rigidity.
So it moves with illness, treatment, exposures and hormones, I guess, in ways that partly overlap with its siblings. It is also not the strongest blood-derived predictor around: a UK Biobank proteomic clock built from 2,923 proteins in 53,021 people showed stronger age-adjusted links to mortality and 18 incident diseases than PhenoAge did.
Whether moving the number means anything clinically is open. A 2026 systematic review concluded that epigenetic clocks should currently be treated as exploratory or adjunctive markers of intervention response, not validated surrogate endpoints. A commentary in the AMA Journal of Ethics goes further, arguing these tests cannot tell how old a person “really” is and calling biological age a fiction. I suppose a fiction can still be a useful one. Passer rating is too.
The logical end of all this is a model that predicts DNAm PhenoAge from creatinine, glucose, C-reactive protein and six other routine lab values. It will agree with DNAm PhenoAge extremely well, and it will be the original.
Sources
- Epigenetic Clocks Power Biological Age Data, But Why Do Results Differ Across Tests? | The Scientist
- Elysium Health Launches At-Home Test to Measure Rate of Aging, Biological Age
- The Science Behind Index | Elysium Health
- The Sociodemographic and Lifestyle Correlates of Epigenetic Aging in a Nationally Representative U.S. Study of Younger Adults
- Development and validation of a simplified biological clock (GeroAge) to estimate accelerated aging in patients with cancer and its influence on clinical outcomes: a cohort study
- Prenatal and childhood lead exposure is prospectively associated with biological markers of aging in adolescence
- Choosing Epigenetic Clock Models: Horvath, Hannum, PhenoAge, GrimAge and Beyond - CD Genomics
- Figures and data in DunedinPACE, a DNA methylation biomarker of the pace of aging | eLife
- A 25 Component Blood Biomarker Aging Clock Improves on 9 Component PhenoAge – Fight Aging!
- Proteomic aging clock (PAC) predicts age-related outcomes in middle-aged and older adults
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study | PLOS Medicine
- Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial.
- Associations of Epigenetic Age Acceleration with Motor Impairment: Evidence from the PPMI Cohort
- Associations of Organophosphate Pesticide Metabolite Mixtures with Epigenetic Age Acceleration
- Concordance between changes in epigenetic clocks and changes in clinical outcomes in geroscience intervention trials: A systematic review
- What Are the Most Ethically Salient Implications of Epigenetic Age Testing? – Dec 2025 | Journal of Ethics | American Medical Association
- Cortisol, DHEAS, and the cortisol/DHEAS ratio as predictors of epigenetic age acceleration
Bio Clock Test explains published research. It is not medical advice and it does not diagnose anything. We never recommend a test, a supplement or a treatment. Talk to a clinician about your health.